Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NOVOPHARM MOVING INTO U.S. PRIVATE LABEL BUSINESS WITH GRANUTEC ACQUISITION

This article was originally published in The Tan Sheet

Executive Summary

NOVOPHARM MOVING INTO U.S. PRIVATE LABEL BUSINESS WITH GRANUTEC ACQUISITION from Roussel Uclaf Holdings, Toronto-based Novopharm announced on May 25. Terms of the deal were not disclosed. Novopharm predicted that the acquisition would be completed by June 30. Granutec OTC private label sales are expected to reach $ 40 mil. in 1993, up approximately 25% from the $ 32 mil. in sales generated in 1992. Novopharm Chairman and CEO Leslie Dan said that Granutec's headquarters in Wilson, N.C. will "eventually" be converted into Novopharm's U.S. manufacturing base. Novopharm is the leading manufacturer of branded prescription generic drugs in Canada, and the lion's share of the products it sells in the U.S. currently are manufactured in Canada. The company also sells private label OTCs through its Vancouver-based Stanley Pharmaceuticals subsidiary to retail chains in Canada. Privately held Novopharm's sales are currently annualizing at $ 240 mil. (approximately $ 300 mil. [Canadian]). "Our future plans include building new manufacturing facilities in Wilson and enlarging our facilities in Largo, Fla.," Dan said. "This will result in more than [double] the production capacity of the facilities, increased local employment, as well as an expanded market for Novopharm." The company plans to use the new and expanded facilities to manufacture branded generics, private label OTCs and "innovative pharmaceuticals that are currently under development."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel